Plain-English translation of NCT07169500 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new treatment called BCMA-CART for young adults with multiple myeloma. This medication uses specialized immune cells designed to recognize and attack myeloma cancer cells. Depending on your overall health and disease status, you may receive the treatment alone or combined with a stem cell transplant beforehand.
Multiple myeloma is a serious blood cancer, and doctors are looking for more effective ways to treat it, especially in younger patients. This medication represents a newer approach using the body's own immune system to fight cancer cells.
You likely qualify if…
You likely don't qualify if…
If you qualify, your doctors will first assess whether you need a stem cell transplant based on your disease status. Those who need it will undergo the transplant first; others will proceed directly to receiving the BCMA-CART cell therapy. You will have regular visits for monitoring, blood tests, and evaluations to track how well the treatment is working and to watch for any side effects. The study will follow your health closely over time to understand both the safety and effectiveness of this new treatment.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China